This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Ovagen (20 mg Vial)
Ovagen is a synthetic ultrashort tripeptide (Glu-Asp-Leu; EDL) studied as a bioregulator of gastrointestinal and liver tissues[1]. In vitro studies demonstrate that EDL increases cell proliferation and modulates aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures[2]. No controlled human trials exist; available data are preclinical and cell-based.
Quick Reference
What is Ovagen?
Research overview based on the cited scientific literature.
• Goal: Support gastrointestinal and hepatic tissue bioregulation over time[1].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality[4][5].
• Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; for long-term stability, −80 °C (−112 °F) is optimal.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within a few days or aliquot and freeze to minimize hydrolysis.
• Do not store thawed solution longer than 1–2 days at 2–8 °C; avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Ovagen studied?
Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis[1][6]. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, suggesting cytoprotective effects[2]. Such ultrashort peptides are known to influence cell differentiation, proliferation, and apoptosis via gene regulation[3]. Additionally, EDL has been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site[7].
What does the research report about Ovagen?
Observations from preclinical and in vitro literature (no controlled human trials available).
• May support gastrointestinal and hepatic tissue bioregulation based on ultrashort peptide bioregulator research[1].
• In vitro studies indicate potential cytoprotective effects via modulation of aging-related gene expression[2].
• Ultrashort peptides generally exhibit rapid metabolism and low immunogenicity[6].
• Side effects are not well characterized due to lack of human clinical data; mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Ovagen?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.